Collaboration Agreements - Additional Information (Details)	1 Months Ended	12 Months Ended
	Nov. 30, 2017 USD ($) Milestone TargetAntigen	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of target antigens against which antibodies are to be identified and selected | TargetAntigen	2
Revenue		$ 570,000	$ 275,000
Surface Oncology, Inc.
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of target antigens against which antibodies are to be identified and selected | TargetAntigen	2
Upfront payments fee received	$ 250,000
Number of designated milestones | Milestone	4
Revenue		500,000
Annual maintenance fee			50,000
Surface Oncology, Inc. | Exclusive Product License
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue		$ 500,000
Annual maintenance fee			$ 50,000